Patents by Inventor Tatiana Novobrantseva

Tatiana Novobrantseva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
    Patent number: 11884919
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: January 30, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE
    Publication number: 20220243199
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA
    Type: Application
    Filed: September 14, 2021
    Publication date: August 4, 2022
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • METHODS OF DELIVERING OLIGONUCLEOTIDES TO IMMUNE CELLS
    Publication number: 20220079970
    Abstract: The invention relates to the field of delivery of nucleic acid-based agents to immune cells.
    Type: Application
    Filed: April 29, 2021
    Publication date: March 17, 2022
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Tatiana Novobrantseva, Akin Akinc, Tsukasa Sugo
  • SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
    Publication number: 20220074925
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: April 2, 2021
    Publication date: March 10, 2022
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene
    Patent number: 11149273
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: October 19, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
    Publication number: 20210155937
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Application
    Filed: July 7, 2020
    Publication date: May 27, 2021
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
    Publication number: 20210087218
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Application
    Filed: May 6, 2020
    Publication date: March 25, 2021
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • Compositions and methods for inhibiting expression of CD274/PD-L1 gene
    Patent number: 10745704
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: August 18, 2020
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE
    Publication number: 20200239887
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA
    Type: Application
    Filed: October 3, 2019
    Publication date: July 30, 2020
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
    Publication number: 20200225215
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: June 14, 2019
    Publication date: July 16, 2020
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Compositions and methods directed to treating liver fibrosis
    Patent number: 10669303
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 2, 2020
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Gregory Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • Methods of treating conditions with antibodies that bind B7-H4
    Patent number: 10626176
    Abstract: Provided herein are embodiments relating to therapeutic applications of B7-H4 antibodies.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: April 21, 2020
    Assignee: JOUNCE THERAPEUTICS, INC.
    Inventors: Sriram Sathyanarayanan, Tatiana Novobrantseva, Virna Cortez-Retamozo
  • Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
    Patent number: 10472628
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 12, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE
    Publication number: 20190048352
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Application
    Filed: February 27, 2018
    Publication date: February 14, 2019
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt
  • COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
    Publication number: 20190016751
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Application
    Filed: February 26, 2018
    Publication date: January 17, 2019
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Greg Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • METHODS OF DELIVERING OLIGONUCLEOTIDES TO IMMUNE CELLS
    Publication number: 20180369271
    Abstract: The invention relates to the field of delivery of nucleic acid-based agents to immune cells.
    Type: Application
    Filed: February 20, 2018
    Publication date: December 27, 2018
    Applicant: Arbutus Biopharma Corporation
    Inventors: Tatiana Novobrantseva, Akin Akinc, Tsukasa Sugo
  • Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene
    Publication number: 20180282725
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA
    Type: Application
    Filed: December 19, 2017
    Publication date: October 4, 2018
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • SCREENING METHOD FOR SELECTED AMINO-LIPID-CONTAINING COMPOSITIONS
    Publication number: 20180209963
    Abstract: The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-dimethylaminomethyl-[1-3]-dioxolane by screening for an effect of the agent on the liver of a model subject.
    Type: Application
    Filed: September 1, 2017
    Publication date: July 26, 2018
    Applicant: Arbutus Biopharma Corporation
    Inventors: Marco A. Ciufolini, Thomas D. Madden, Michael J. Hope, Barbara Mui, Antonin de Fougerolles, Tatiana Novobrantseva, Anna Borodovsky, Akin Akinc, Mark Tracy, Pieter Rutter Cullis
  • Compositions and methods directed to treating liver fibrosis
    Patent number: 9944671
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: April 17, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Greg Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • Compositions and methods for inhibiting expression of CD274/PD-L1 gene
    Patent number: 9932593
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CD274/PD-L1 gene, and methods of using such dsRNA compositions to inhibit expression of CD274/PD-L1.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: April 3, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Antonin DeFougerolles, Tatiana Novobrantseva, Brian Bettencourt